Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
RAPT Therapeutics ( (RAPT) ) has issued an update.
RAPT Therapeutics announced their plans for the development of RPT904, a potential best-in-class treatment for food allergies and chronic spontaneous urticaria, with significant market opportunities. The company anticipates multiple milestones over the next two years, including Phase 2b trials and data releases, which could enhance their industry positioning and offer new treatment options for patients.
The most recent analyst rating on (RAPT) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.
Spark’s Take on RAPT Stock
According to Spark, TipRanks’ AI Analyst, RAPT is a Underperform.
RAPT Therapeutics’ overall stock score reflects significant challenges, primarily due to its inability to generate revenue and consistent operational losses. The strong equity position in the balance sheet is a positive, but technical indicators suggest a continued downward trend. The negative valuation metrics further highlight the risks associated with the stock.
To see Spark’s full report on RAPT stock, click here.
More about RAPT Therapeutics
RAPT Therapeutics, Inc. is a company focused on developing transformative therapies for high-value inflammatory diseases. Their primary product, RPT904, is a novel anti-IgE antibody designed for less frequent dosing and greater compliance, targeting food allergies and chronic spontaneous urticaria.
Average Trading Volume: 114,964
Technical Sentiment Signal: Sell
Current Market Cap: $134.9M
For detailed information about RAPT stock, go to TipRanks’ Stock Analysis page.